April 13, 2024

Alpine Immune Sciences Inc ALPN offered the primary medical information of povetacicept in autoimmune glomerulonephritis throughout a late-breaking session on the American Society of Nephrology (ASN) Kidney Week.

In IgAN, therapy with low-dose povetacicept, 80 mg SC each 4 weeks, was related to clinically significant enhancements in proteinuria, with a 53.5% discount from baseline in UPCR (n=5) at 24 weeks. 

As well as, at 24 weeks, 4/5 (80%) had achieved remission, as outlined as UPCR < 0.5 g/g and ≥50% discount in UPCR from baseline with steady renal perform (≤ 25% discount in eGFR from baseline).

In IgAN, therapy with low-dose povetacicept was additionally related to a >60% discount in the important thing disease-related biomarker galactose-deficient IgA1 (Gd-IgA1), in addition to steady renal perform as assessed by estimated glomerular filtration price (eGFR) (+7.1% from baseline at 24 weeks; n=5).

The primary participant with major membranous nephropathy (pMN), additionally handled with povetacicept 80 mg SC each 4 weeks, achieved an immunological remission, outlined as a discount within the extremely disease-relevant biomarker anti-PLA2R1 to an undetectable degree, from a baseline of 209 to < 2 RU/mL by 22 weeks.

Povetacicept has been nicely tolerated, with no reported administration-associated reactions, no situations of IgG < 3 g/L, and no extreme infections.

A better dose of povetacicept, 240 mg SC each 4 weeks, continued to enroll, with preliminary information anticipated in 1H 2024.

Value Motion: ALPN shares are up 39.35% at $14.66 on the final examine Thursday.

Supply Hyperlink : hagportfolio.com